var title_f42_59_43952="Clindamycin: Patient drug information";
var content_f42_59_43952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clindamycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/49/35604?source=see_link\">",
"       Clindamycin (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=see_link\">",
"       Clindamycin (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12228 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-218.28.111.102-E73EFF4BA8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43952=[""].join("\n");
var outline_f42_59_43952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/49/35604?source=related_link\">",
"      Clindamycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=related_link\">",
"      Clindamycin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43953="Ankle eversion stress test";
var content_f42_59_43953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Ankle eversion stress test (crossed leg test)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 651px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The crossed-leg test is used to detect high ankle (syndesmotic) sprain. When the examiner applies downward pressure to the medial side of the knee (black arrow), the patient will have pain in the distal tibiofibular syndesmosis complex (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43953=[""].join("\n");
var outline_f42_59_43953=null;
var title_f42_59_43954="Hymenolepiasis diminuta eggs";
var content_f42_59_43954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Hymenolepiasis diminuta eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Eggs of",
"    <em>",
"     Hymenolepis diminuta",
"    </em>",
"    . These eggs are round or slightly oval, size 70 to 85 micrometers by 60 to 80 micrometers, with a striated outer membrane and a thin inner membrane. The space between the membranes is smooth or faintly granular. The oncosphere has six hooks. There are no polar filaments extending into the space between the oncosphere and the outer shell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Hymenolepiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43954=[""].join("\n");
var outline_f42_59_43954=null;
var title_f42_59_43955="Patient information: Swollen neck nodes in children (The Basics)";
var content_f42_59_43955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17190\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/38/15968\">",
"         Lymph nodes in a child's neck",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/32/28161\">",
"         Patient information: Animal bites (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/10/23714\">",
"         Patient information: Hodgkin lymphoma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/33/41489\">",
"         Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/57/25489\">",
"         Patient information: Tuberculosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/15/22770\">",
"         Patient information: Animal bites (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/11/176\">",
"         Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/44/40643\">",
"         Patient information: The common cold in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/35/39475\">",
"         Patient information: Tuberculosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Swollen neck nodes in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/swollen-neck-nodes-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31112623\">",
"      <span class=\"h1\">",
"       What are &ldquo;nodes?&rdquo;",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nodes, short for &ldquo;lymph nodes,&rdquo; are bean-shaped organs that are part of the body&rsquo;s lymphatic system. The lymphatic system makes and stores cells that fight infections. People have groups of nodes all over their body, including in the neck, armpits, and groin area.",
"     </p>",
"     <p>",
"      Normally, nodes are small. You might not be able to feel or see them under your child&rsquo;s skin. But if your child&rsquo;s nodes get big and swollen, you might be able to feel or see them under the skin. The terms doctors use for nodes that are big and swollen are \"lymphadenopathy\" or \"lymphadenitis.\" &nbsp;",
"     </p>",
"     <p>",
"      Nodes can get swollen over a few days. Doctors call this &ldquo;acute&rdquo; lymphadenopathy or lymphadenitis. Nodes can also get swollen over weeks to months. Doctors call this &ldquo;chronic&rdquo; lymphadenopathy or lymphadenitis.",
"     </p>",
"     <p>",
"      This article discusses swollen nodes in the neck (",
"      <a class=\"graphic graphic_figure graphicRef82564 \" href=\"mobipreview.htm?15/38/15968\">",
"       figure 1",
"      </a>",
"      ). But children can get swollen nodes in other parts of their body, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112638\">",
"      <span class=\"h1\">",
"       What causes swollen neck nodes in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different conditions can cause swollen neck nodes in children. The 2 main causes are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Infections &ndash; Swollen neck nodes are usually caused by an infection. Different infections can cause swollen neck nodes. Some infections, such as the common cold, are caused by viruses. Other infections, such as some sore throats, are caused by bacteria.",
"       </li>",
"       <li>",
"        Conditions that are not infections &ndash; These can include diseases that affect certain tissues in the body (called &ldquo;connective tissue diseases&rdquo;) or cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112653\">",
"      <span class=\"h1\">",
"       What are the symptoms of swollen neck nodes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Swollen neck nodes are large lumps that you can see or feel on the front, sides, or back of your child&rsquo;s neck. Swollen neck nodes are sometimes painful, especially when touched. Also, the skin around swollen neck nodes is sometimes red or warm.",
"     </p>",
"     <p>",
"      Children can have other symptoms, too, depending on what&rsquo;s causing the swollen neck nodes. For example, if the common cold is causing the swollen neck nodes, your child can have a runny nose, stuffy nose, or cough.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112668\">",
"      <span class=\"h1\">",
"       Should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you see or feel a swollen neck node on your child, tell his or her doctor or nurse.",
"     </p>",
"     <p>",
"      Because different conditions can cause swollen neck nodes, the doctor or nurse will probably want to examine your child to find the cause.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112683\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse will ask about your child&rsquo;s symptoms and do an exam. He or she might do tests to see what&rsquo;s causing the swollen neck nodes. The tests will depend on how long the nodes have been swollen, if your child has swollen nodes in other parts of the body, and your child&rsquo;s other symptoms.",
"     </p>",
"     <p>",
"      The tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Lab tests &ndash; For example, the doctor or nurse can use a cotton swab to get a sample from the back of your child&rsquo;s throat. Or, if the node has pus in it, he or she can use a needle to get a sample of pus from the node. These samples will be sent to a lab for tests.",
"       </li>",
"       <li>",
"        An imaging test, such as an ultrasound or CT scan &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A biopsy &ndash; During a biopsy, the doctor will remove the node or a small sample of tissue from the node. Then another doctor will look at the sample under a microscope.",
"       </li>",
"       <li>",
"        A skin test for an infection called &ldquo;tuberculosis&rdquo; &ndash; This test involves getting a shot under the skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112698\">",
"      <span class=\"h1\">",
"       How are swollen neck nodes in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what&rsquo;s causing the swollen neck nodes and your child&rsquo;s symptoms.",
"     </p>",
"     <p>",
"      Most swollen neck nodes in children do not need treatment, because they are caused by the common cold. The nodes will get smaller when the cold gets better.",
"     </p>",
"     <p>",
"      Swollen neck nodes that are caused by a bacterial infection usually need treatment with antibiotic medicines. Most children can take these medicines by mouth at home. But if your child has a severe infection, he or she might need treatment in the hospital. There, the doctor will give your child antibiotics into a vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      If your child has a pus-filled neck node that doesn&rsquo;t get better with antibiotics, the doctor might need to drain the pus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31112713\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/33/41489?source=see_link\">",
"       Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/10/23714?source=see_link\">",
"       Patient information: Hodgkin lymphoma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25489?source=see_link\">",
"       Patient information: Tuberculosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=see_link\">",
"       Patient information: Animal bites (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"       Patient information: The common cold in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39475?source=see_link\">",
"       Patient information: Tuberculosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=see_link\">",
"       Patient information: Animal bites (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"       Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?42/59/43955?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17190 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43955=[""].join("\n");
var outline_f42_59_43955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112623\">",
"      What are &ldquo;nodes?&rdquo;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112638\">",
"      What causes swollen neck nodes in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112653\">",
"      What are the symptoms of swollen neck nodes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112668\">",
"      Should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112683\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112698\">",
"      How are swollen neck nodes in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31112713\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/38/15968\">",
"      Lymph nodes in a child's neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=related_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/10/23714?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=related_link\">",
"      Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/33/41489?source=related_link\">",
"      Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25489?source=related_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43956="Ezogabine: Patient drug information";
var content_f42_59_43956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ezogabine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     see \"Ezogabine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13365445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Potiga&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13365421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13365420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3558582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ezogabine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13365425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13365426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble moving around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13365427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13365423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13365424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13365428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13365429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17071 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43956=[""].join("\n");
var outline_f42_59_43956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365445\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365421\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365420\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365425\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365426\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365427\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365423\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365424\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365428\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365429\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=related_link\">",
"      Ezogabine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43957="MRI cluster of breast cysts";
var content_f42_59_43957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    MRI cluster of breast cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T2 weighted MRI image of the breast (A) reveals hyperintense, small clustered cysts (red arrow), and larger isolated cysts (green arrows). The cysts do not show enhancement on the T1-weighted fat saturated post contrast sequence (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43957=[""].join("\n");
var outline_f42_59_43957=null;
var title_f42_59_43958="Lymph infiltr nerve vessel";
var content_f42_59_43958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic lymphocytic inflammation in blood vessel supplying a nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nerve biopsy revealing chronic lymphocytic inflammation and fibrinoid necrosis within the wall of an artery/arteriole supplying a peripheral nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43958=[""].join("\n");
var outline_f42_59_43958=null;
var title_f42_59_43959="Overview of treatment for head and neck squamous cell cancer";
var content_f42_59_43959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment for head and neck squamous cell cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Benedito A Carneiro, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Shiyu Song, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43959/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/59/43959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancers arise from a variety of sites within the head and neck region, which is divided into five basic areas (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"mobipreview.htm?26/56/27525\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The oral cavity, which includes the lips, buccal mucosa, anterior tongue, floor of the mouth, hard palate, upper gingiva, lower gingiva, and retromolar trigone (",
"      <a class=\"graphic graphic_figure graphicRef54845 \" href=\"mobipreview.htm?3/27/3509\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pharynx, which is divided into the oropharynx, the nasopharynx, and the hypopharynx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The nasopharynx, the narrow tubular passage behind the nasal cavity, is the upper part of the pharynx.",
"     </li>",
"     <li>",
"      The oropharynx, the middle part of the pharynx, includes the tonsillar area, the tongue base, the soft palate, and the posterior pharyngeal wall.",
"     </li>",
"     <li>",
"      The hypopharynx, which is the lower part of the pharynx, includes the pyriform sinuses, the posterior surface of the larynx (postcricoid area) and the inferoposterior, and inferolateral pharyngeal walls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The larynx (voice box) contains the vocal cords and epiglottis. It is divided into three anatomic regions: the supraglottic larynx, the glottic larynx (true vocal cords and the anterior and posterior commissures) and the subglottic larynx (",
"      <a class=\"graphic graphic_figure graphicRef58555 \" href=\"mobipreview.htm?22/27/22967\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72411 \" href=\"mobipreview.htm?28/61/29654\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nasal cavity and the paranasal sinuses, which include the maxillary, ethmoid, sphenoid, and frontal sinuses (",
"      <a class=\"graphic graphic_figure graphicRef78790 \" href=\"mobipreview.htm?20/18/20769\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The major salivary glands (parotid, submandibular, and sublingual (",
"      <a class=\"graphic graphic_figure graphicRef62744 \" href=\"mobipreview.htm?6/19/6449\">",
"       figure 6",
"      </a>",
"      )) and the minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract, including the oral cavity (especially the palate), paranasal sinuses, larynx, and pharynx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most head and neck cancers begin in the mucosal surfaces of the head and neck region (upper aerodigestive tract) and are predominantly squamous cell carcinomas. An overview of treatment for head and neck squamous cell carcinomas will be presented here.",
"   </p>",
"   <p>",
"    Cancers of the brain, thyroid, eye, ear, scalp, skin, teeth, bones (including skull base), and muscles are not included with squamous cell cancers of the head and neck, and many of these are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link\">",
"       \"Overview of the management of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=see_link\">",
"       \"Anaplastic thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=see_link\">",
"       \"Parathyroid carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=see_link\">",
"       \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=see_link\">",
"       \"Treatment and prognosis of basal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"       \"Chordoma and chondrosarcoma of the skull base\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"       \"Head and neck sarcomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10821?source=see_link\">",
"       \"Tracheal tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18480380\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43959/abstract/1\">",
"     1",
"    </a>",
"    ]. The T classifications indicate the extent of the primary tumor and are site specific; there is considerable overlap in the cervical node (N) classifications.",
"   </p>",
"   <p>",
"    TNM staging tables are separated according to head and neck site.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral cavity (",
"      <a class=\"graphic graphic_table graphicRef70195 \" href=\"mobipreview.htm?38/12/39117\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasopharynx (",
"      <a class=\"graphic graphic_table graphicRef57392 \" href=\"mobipreview.htm?34/8/34957\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oropharynx (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"mobipreview.htm?35/55/36733\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypopharynx (",
"      <a class=\"graphic graphic_table graphicRef55865 \" href=\"mobipreview.htm?36/42/37549\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Larynx (",
"      <a class=\"graphic graphic_table graphicRef66619 \" href=\"mobipreview.htm?22/14/22766\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal cavity and paranasal sinuses (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"mobipreview.htm?9/42/9902\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Salivary glands (",
"      <a class=\"graphic graphic_table graphicRef61042 \" href=\"mobipreview.htm?34/52/35661\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general approach to the diagnosis and staging of head and neck cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY STAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 40 percent of patients with head and neck squamous cell carcinomas (HNSCCs) present with early (stage I and II) disease. In general, these patients are treated with either primary surgery or definitive radiation therapy (RT). Patients with carcinoma in situ usually are managed in the same way as those with T1 disease. Careful observation thereafter constitutes adequate follow-up both for recurrence or development of new primaries. Five-year overall survival in patients with stage I or stage II disease is typically 70 to 90 percent. However, in patients with tobacco and alcohol related cancers, a 20 percent rate of second malignancy might be expected over five years.",
"   </p>",
"   <p>",
"    Because both modalities result in similar rates of local control and survival, the choice is typically based upon surgical accessibility of the tumor and the functional outcomes and morbidity associated with each modality. In general, surgery is used as the main modality of treatment in the oral cavity, whereas RT is more commonly used in the other mucosal sites.",
"   </p>",
"   <p>",
"    When surgery is used, traditional surgical approaches, ie, wide local excision, are usually used for oral cavity cancers, which are easily accessible. Minimally invasive surgery techniques, such as transoral laser resection and robotic surgery, have demonstrated improvements in access, functional outcomes, and morbidity for cancers at other sites, such as the oropharynx and larynx, which are not easily approached with standard surgical approaches.",
"   </p>",
"   <p>",
"    Definitive radiation therapy (RT) approaches incorporate external beam therapy and brachytherapy. As with surgery, advances in RT techniques and delivery, such as three-dimensional conformal treatment planning (3D-CRT, intensity modulated RT [IMRT] and image-guided RT [IGRT]), have demonstrated improved efficacy and reduced morbidity.",
"   </p>",
"   <p>",
"    For patients treated with primary surgery, postoperative RT with or without concurrent chemoradiation is indicated for close or positive margins and other risk factors including perineural invasion and lymphovascular invasion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific recommendations for pretreatment evaluation and treatment are described according to HNSCC site.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/29/32217?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3174?source=see_link&amp;anchor=H636375187#H636375187\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oropharynx\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The larynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18482222\">",
"    <span class=\"h1\">",
"     ADVANCED STAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, local therapy alone, ie, primary surgery or definitive radiation therapy (RT), for locoregionally advanced (stage III, IVA, and IVB) head and neck squamous cell carcinomas resulted in high rates of locoregional recurrence and considerable morbidity, including loss of tongue and larynx function (speech and swallowing). The risk for distant metastasis after local therapy is also high. The integration of chemotherapy into standard surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT has improved survival and permitted organ function preservation for many patients with locoregionally advanced cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43959/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective approaches for locoregionally advanced head and neck squamous cell carcinomas include primary surgery followed by either postoperative RT or concurrent chemoradiation, induction chemotherapy (the addition of chemotherapy prior to surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT), concurrent chemoradiotherapy, and sequential therapy (induction chemotherapy followed by concurrent chemoradiotherapy). Decisions about the sequencing and selection of surgery, RT,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy should be made with multidisciplinary input; tailored to the individual patient, disease sites, and the likely functional consequences and morbidity of each treatment approach; and take into account the experience and technology available at the medical institution. The efficacy, indications, and application of these approaches are discussed separately.",
"   </p>",
"   <p>",
"    Surgery is generally preferred for oral cavity squamous cell carcinomas since most cases are easily accessible, and simultaneous resection and reconstruction can be accomplished with acceptable functional outcomes. However, since oral cavity tumors are aggressive cancers with high rates of locoregional recurrence, postoperative RT with or without chemotherapy should be strongly considered. Definitive RT, concurrent chemoradiation, and sequential therapy are typically reserved for patients who are medically inoperable, who have unresectable disease, or who have resectable disease where surgical resection cannot be accomplished with acceptable long-term functional consequences (eg, total glossectomy).",
"   </p>",
"   <p>",
"    In contrast, organ sparing approaches rather than primary surgery are preferred for most patients with resectable cancers of the oropharynx, hypopharynx, and larynx. Concurrent chemoradiotherapy is a standard option for organ function preservation, but sequential therapy may be preferable in certain circumstances, in particular, for patients with advanced primary tumors (T4b)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced nodal disease. Unresectable cancers of the oropharynx, hypopharynx, and larynx are treated with concurrent chemoradiotherapy or sequential therapy. Definitive RT remains a treatment option for elderly patients and those with a poor performance status.",
"   </p>",
"   <p>",
"    The efficacy, indications, and application of organ sparing approaches are discussed separately, as is definitive and postoperative RT.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"       \"Postoperative radiation therapy in the management of head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for treatment (and pretreatment evaluation) are presented according to disease site.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1321?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339242\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancers occurring at certain sites have different histology and biology than typical squamous cell carcinomas and have particular treatment considerations. These include the nasopharynx, nasal vestibule and cavity, paranasal sinuses, and salivary glands,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in certain circumstances, ie, cancer of unknown primary and human papilloma-virus associated squamous cell carcinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339249\">",
"    <span class=\"h2\">",
"     Nasopharyngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal cancer differs from other head and neck cancers in its epidemiology, pathology, natural history, and treatment. Radiation therapy (RT) is the mainstay of treatment for nasopharyngeal cancer, but the integration of chemotherapy has been instrumental in improving survival for advanced stage disease. Surgery is not typically used because of the deep anatomical location of the nasopharynx and its close proximity to critical neurovascular structures and the base of skull.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339256\">",
"    <span class=\"h2\">",
"     Nasal vestibule and nasal cavity cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of the nasal vestibule are essentially skin cancers and are treated with surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT, depending on size and location within the nasal vestibule. Cancers of the nasal cavity are similar to those that occur in the paranasal sinuses, and have a wide variety of histologies. Both early and moderately advanced tumors of the nasal cavity are treated with surgical resection and postoperative radiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=see_link\">",
"     \"Cancer of the nasal vestibule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339263\">",
"    <span class=\"h2\">",
"     Paranasal sinus cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paranasal sinus cancers encompass multiple histologies, with adenocarcinoma and squamous cell carcinoma being predominant. Aggressive surgical resection remains the mainstay of treatment, but multimodality approaches with surgery, RT, and chemotherapy may be appropriate for certain histologies and for advanced stage cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=see_link\">",
"     \"Paranasal sinus cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339270\">",
"    <span class=\"h2\">",
"     Salivary gland cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors represent a wide array of benign and malignant histologies that occur in salivary gland tissue throughout the head and neck. Surgical extirpation of the salivary gland is important in diagnosis and treatment. Patients with benign and low-grade tumors are typically treated with surgery alone, whereas patients with high-grade carcinomas and other high-risk features are usually treated with surgery and postoperative RT.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=see_link\">",
"       \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28313?source=see_link\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339277\">",
"    <span class=\"h2\">",
"     Cancer of unknown primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma of occult (unknown) primary that involves the upper cervical lymph nodes most likely originated from a head and neck primary, while squamous cell carcinomas involving the lower neck may represent metastases from a head and neck, esophagus, lung, gastrointestinal, or genitourinary tract primary. Patients without other obvious sites of metastatic disease (eg, lung, liver, or bone) should be treated with definitive therapy for locoregional disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19911?source=see_link\">",
"     \"Head and neck squamous cell carcinoma of unknown primary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527339284\">",
"    <span class=\"h2\">",
"     Human papillomavirus associated oropharyngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) infection has been established as a causative agent for certain head and neck squamous cell carcinomas. HPV associated tumors occur primarily in the oropharynx (tonsils and base of tongue), account for the changing epidemiology of oropharyngeal squamous cell carcinoma, and define a subset of patients with poorly differentiated head and neck squamous cell carcinomas that have frequent lymph node involvement but an improved treatment outcome. However, the use of HPV status in clinical decision making remains investigational at this time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LOCALLY RECURRENT AND METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with recurrent disease have a poor prognosis, with a median survival of six to nine months. Treatment options are limited by previous treatment received. All patients with locoregionally recurrent disease should be evaluated for distant metastases prior to initiating retreatment. Those with a good performance status and whose disease is confined to the head and neck may benefit from surgical salvage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reirradiation. However, many patients with locally recurrent and metastatic disease are most appropriate for palliative chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supportive care.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9559?source=see_link\">",
"       \"Treatment of locally recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38265?source=see_link\">",
"       \"Reirradiation for locally recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18482780\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck squamous cell carcinomas frequently metastasize to the cervical lymph nodes, an occurrence that has a markedly negative impact on prognosis. Consequently, treatment of the cervical neck nodes, even if involvement is clinically occult, is often part of the treatment strategy.",
"   </p>",
"   <p>",
"    The risk of developing nodal metastases varies by primary tumor site and factors such as size, histology, tumor thickness, and perineural invasion. Most agree that when the probability of occult metastases exceeds 20 percent, the risk of neck recurrence without elective (prophylactic) treatment is sufficiently high to outweigh the morbidity of neck dissection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irradiation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION AND REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of the mandible, palate, and the larynx can lead to problems in airway management, mastication, deglutition, speech, and cosmesis. Function is also impaired by radiation therapy and chemoradiotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prosthetic rehabilitation of patients with hard palate defects (the result of tumor resections involving the maxilla) consists of placement of an obturator prosthesis, which serves to restore orofacial functions, including deglutition, control of secretions, mastication, and phonetics, and to aesthetically replace the missing orofacial structures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"       \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical reconstruction alone or combined with an obturator prosthesis can be used to remedy palatal defects. In addition, a variety of reconstruction options, including free flaps and autogenous bone grafts, are available to restore mandibular defects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=see_link\">",
"       \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Speech and swallowing rehabilitation are critical to restoring function and quality of life following both surgery and radiation therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"       \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"       \"Alaryngeal speech rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1334172873\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-related toxicity associated with treatment, whether surgery, radiation therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy, for head and neck cancer is substantial and negatively impacts upon patient quality of life. These complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1334172913\">",
"    <span class=\"h1\">",
"     POSTTREATMENT EVALUATION AND SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon completion of therapy, posttreatment imaging is important to evaluate for residual disease and establish a baseline. However, imaging should not be performed too soon. Obtaining imaging studies, in particular positron emission tomography-computed tomography (PET-CT) scans, prior to 12 weeks following treatment can lead to false positive results. We recommend waiting at least four to six weeks following radiation or chemoradiation therapy for CT scans or magnetic resonance imaging (MRI) and 8 to 12 weeks for PET scans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular posttreatment follow-up has become an essential part of the care of patients after potentially curative treatment of head and neck cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur within this timeframe, while the risk of second primary malignancy is higher than recurrence risk for most patients beyond three years. However, continued follow-up is generally suggested since the risk of recurrence (and second primary malignancy) remains elevated beyond the first five years, especially for cancers of the hypopharynx, larynx, nasopharynx, and salivary glands. Because of the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits for these patients and continue for longer duration (ie, beyond five years).",
"   </p>",
"   <p>",
"    Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications and smoking cessation counseling, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/20/8515?source=see_link\">",
"       \"Patient information: Throat cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18482966\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of treatment for head and neck squamous cell carcinoma depends upon tumor site and stage, the functional outcomes and morbidity associated with various treatment approaches, and patient-related factors, such as performance status, comorbidities, and preference. A multidisciplinary approach, including surgeons, medical oncologists, and radiation oncologists, as well as dentists, dieticians, and rehabilitation therapists, is generally required for treatment planning and managing patients with head and neck cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with early (stage I and II) head and neck carcinomas are generally managed with single modality treatment, either surgery or radiation therapy (RT). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Early stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with advanced (stage III, IVA, and IVB) cancers are typically managed with multimodality treatment; organ function sparing approaches are preferred. For patients who are treated with a functional organ preservation approach, we recommend concurrent chemoradiotherapy rather than induction chemotherapy alone. The use of induction therapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) may offer additional advantages in select situations. Concurrent chemoradiotherapy is preferable for patients less likely to have distant metastases (N0 and N1 presentations) and sequential therapy may be preferable for select patients with high risk of distant metastases (more extensive lymph node disease including bulky N2b, N2c, and N3). (See",
"      <a class=\"local\" href=\"#H18482222\">",
"       'Advanced stage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with locally recurrent and metastatic disease are most appropriate for palliative chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      supportive care, but select patients with disease confined to the head and neck may benefit from surgical salvage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reirradiation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Locally recurrent and metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the cervical neck nodes, even if involvement is clinically occult, is often part of the treatment strategy for HNSCC. (See",
"      <a class=\"local\" href=\"#H18482780\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer. (See",
"      <a class=\"local\" href=\"#H1334172913\">",
"       'Posttreatment evaluation and surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43959/abstract/2\">",
"      Furness S, Glenny AM, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2010; :CD006386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43959/abstract/3\">",
"      Pignon JP, le Ma&icirc;tre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3380 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43959=[""].join("\n");
var outline_f42_59_43959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18482966\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18480380\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY STAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18482222\">",
"      ADVANCED STAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H527339242\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339249\">",
"      Nasopharyngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339256\">",
"      Nasal vestibule and nasal cavity cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339263\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339270\">",
"      Salivary gland cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339277\">",
"      Cancer of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527339284\">",
"      Human papillomavirus associated oropharyngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LOCALLY RECURRENT AND METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18482780\">",
"      MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECONSTRUCTION AND REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1334172873\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1334172913\">",
"      POSTTREATMENT EVALUATION AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18482966\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3380|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27525\" title=\"figure 1\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/27/3509\" title=\"figure 2\">",
"      Anatomy of the oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/27/22967\" title=\"figure 3\">",
"      Laryngeal anatomy coronal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/61/29654\" title=\"figure 4\">",
"      Laryngeal anatomy sagittal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/18/20769\" title=\"figure 5\">",
"      Paranasal sinus anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/19/6449\" title=\"figure 6\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/12/39117\" title=\"table 1\">",
"      TNM stage oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/8/34957\" title=\"table 2\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/55/36733\" title=\"table 3\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37549\" title=\"table 4\">",
"      TNM stage hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22766\" title=\"table 5\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/42/9902\" title=\"table 6\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/52/35661\" title=\"table 7\">",
"      TNM stage salivary glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/28/19911?source=related_link\">",
"      Head and neck squamous cell carcinoma of unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23241?source=related_link\">",
"      Paranasal sinus cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/20/8515?source=related_link\">",
"      Patient information: Throat cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38265?source=related_link\">",
"      Reirradiation for locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10821?source=related_link\">",
"      Tracheal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/29/32217?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3174?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1321?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15224?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43960="Diffuse idiopathic skeletal hyperostosis (DISH)";
var content_f42_59_43960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diffuse idiopathic skeletal hyperostosis (DISH)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43960/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/59/43960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse idiopathic skeletal hyperostosis (DISH) has several synonyms, including ankylosing hyperostosis and Forestier's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is a noninflammatory disease, with the principal manifestation being calcification and ossification of spinal ligaments and the regions where tendons and ligaments attach to bone (entheses).",
"   </p>",
"   <p>",
"    Radiographic changes characteristic of DISH may occur in the absence of any musculoskeletal symptoms.",
"   </p>",
"   <p>",
"    The clinical manifestations, radiographic findings, and treatment of DISH are reviewed here. The clinical features and treatment of another noninflammatory arthritis, osteoarthritis, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the cause of DISH remains unknown, mechanical factors, dietary contributions, drugs, environmental exposures, and metabolic conditions have been hypothesized to be important. It is thought that the bone formation that is distinctive of DISH results from abnormal osteoblastic differentiation and activity at the enthesis. An appropriate genetic background, as yet unidentified, external factors, or local or systemic factors may stimulate the abnormal osteoblastic differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bony bridging is usually more prominent on the right side of the thoracic spine in patients with DISH. By comparison, those with DISH and dextrocardia or situs inversus have more extensive bony bridging on the left side of the thoracic spine. Thus, mechanical factors associated with the change in location of the aorta may affect the development of bony outgrowths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/3\">",
"     3",
"    </a>",
"    ]. In ossification of the posterior longitudinal ligament of the spine, a condition that can occur with DISH or as an independent entity, ligamentous stretching can increase prostaglandin I2 synthase resulting in stimulation of osteogenic differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a case-control study reported no significant difference in the amount of heavy work performed by persons with DISH than by control individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/5\">",
"     5",
"    </a>",
"    ]. However, work as a measure of mechanical loading of bones and joints is notoriously difficult to assess accurately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Environmental factors and diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several known environmental causes of hyperostosis have been investigated as possible contributors to the development of DISH. In one study, fluoride levels in both the water and air were measured in towns inhabited by 11 patients with DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/6\">",
"     6",
"    </a>",
"    ]. Based upon the levels of fluoride, chronic fluoride intoxication was unlikely to be causative.",
"   </p>",
"   <p>",
"    The relationship between prolonged exposure to an excess of vitamin A and bone hyperostosis is established. However, while higher serum levels of retinol have been reported in DISH patients compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], this has not been confirmed by all investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term therapy of acne and other skin conditions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , a synthetic derivative of vitamin A, is associated with hyperostotic changes in the spine. Etretinate (no longer available for clinical use),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    , and other synthetic retinoids are associated with hyperostosis, particularly at extraspinal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. As noted in the previous section, however, increased exposure to vitamin A alone does not appear to be adequate to cause DISH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-like growth factor-1 stimulates osteoblasts, and growth hormone can induce the local production of insulin-like growth factor-1 in osteoblasts. It is believed that these factors are involved in the pathogenesis of the increased osteoblastic activity in DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. While individual studies evaluating levels of glucose, insulin, insulin-like growth factor-1, and growth hormone have produced conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], some confirmation of their importance comes from clinical studies. As an example, the Pima Indians have a high frequency of DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/17\">",
"     17",
"    </a>",
"    ]. They also have a high prevalence of obesity, elevated blood pressure, adult onset diabetes mellitus, and hyperinsulinemia. In Caucasian populations, the prevalence of DISH is increased in obese persons and possibly in those with early obesity or diabetes mellitus, conditions in which increased levels of insulin are likely present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15,16,18,19\">",
"     15,16,18,19",
"    </a>",
"    ]. Features of DISH are found in up to 20 percent of those with acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/20\">",
"     20",
"    </a>",
"    ]. Elevated levels of insulin, insulin-like growth factor-1, and growth hormone have been reported in some studies of DISH patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/14,21\">",
"     14,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypervascularity of ossified ligaments and involved vertebrae has been described. Whether this causes osteoblast proliferation or is a result from DISH is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet derived growth factor-BB and transforming growth factor-1&szlig; in ligament cells may lead to increased levels of nuclear factor kappa B in DISH. Nuclear factor kappa B can cause undifferentiated mesenchymal cells to differentiate into osteoblasts, providing a plausible mechanism for bony proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Matrix Gla protein likely inhibits bone formation. The apparently paradoxical finding of higher levels of matrix Gla in persons with DISH compared with controls suggests a possible role for this protein in the disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DISH is more common in men than women. The incidence varies by population and increases with age, rarely being diagnosed before the age of 40:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of individuals over age 30 in Finland, the incidence was 0.7 and 0.4 per 100 person years in men and women, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/24\">",
"       24",
"      </a>",
"      ]. In another Finnish study, the prevalence in people over 40 years of age was 3.8 and 2.6 percent in men and women, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/25\">",
"       25",
"      </a>",
"      ]. Among those over age 70, the prevalence was 10.1 and 6.8 percent. In Budapest, the prevalence in those over 50 years was 4.9 percent in men and 1.4 percent in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Pima Indians in Arizona of the United States have a particularly high prevalence of DISH, occurring in 25 and 4.7 percent of men and women aged 15 years and over, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/17\">",
"       17",
"      </a>",
"      ]; this rises to 48 and 12 percent in those over the age of 55 years.",
"     </li>",
"     <li>",
"      American blacks may have a lower prevalence of DISH than whites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hospital-based studies may report a higher prevalence of disease than population-based studies since DISH is more likely among those seeking or requiring hospital care. A hospital-based study of 1500 African blacks found a radiographic prevalence of approximately 4 percent in both males and females over age 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/27\">",
"       27",
"      </a>",
"      ]. A similar study among Jews living in Jerusalem found a prevalence of 22.4 and 13.4 percent in males and females over age 40, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most reports of the clinical features of DISH are based upon clinic or hospital series, individuals evaluated in these studies are more likely to be symptomatic than those in population-based surveys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DISH may have neck, thoracic spine, low back,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extremity pain. One study compared the symptoms among patients with either DISH or lumbar spondylosis and healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15\">",
"     15",
"    </a>",
"    ]. Significantly higher levels of pain over the neck, thoracic spine, low back, and extremities were reported in those with DISH than in healthy persons. Disability as assessed by the Health Assessment Questionnaire was also greater in those with DISH than in healthy subjects. Among those with DISH or symptomatic lumbar spondylosis, there were similar degrees of pain, disability, and diminution in global well-being.",
"   </p>",
"   <p>",
"    The frequency of complaints among those with DISH varies by the site of discomfort. Pain in the thoracic spine, for example, reportedly occurs among 40 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. By comparison, symptoms in the shoulder, elbow, and knee and complaints of dysphagia are less common, being reported in approximately 15 to 25 percent of patients. Spinal morning stiffness, a symptom usually associated with inflammatory disorders of the spine, is present in a significant number of affected individuals (80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1\">",
"     1",
"    </a>",
"    ]. Stridor may rarely occur when large anterior osteophytes arise from C2 to C3; odynophagia and otalgia may result from pressure-induced hypopharyngeal ulceration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some, but not all, studies suggest a link between radiologic findings at a particular site and the presence of symptoms attributed to the abnormality. In one study of hospitalized patients, for example, a significant association was reported between shoulder hyperostosis and shoulder symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/30\">",
"     30",
"    </a>",
"    ]. A near doubling of risk for elbow symptoms was also reported in those with elbow hyperostosis (but it did not reach statistical significance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/31\">",
"     31",
"    </a>",
"    ]. However, unlike the studies cited earlier, no appreciable link was noted between axial hyperostosis and spinal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, a comparison of patients with DISH and controls with spondylosis reported at least a fourfold increase in the frequency of medial epicondylitis, knee enthesitis, plantar fasciitis, and dysphagia in those with DISH versus controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15\">",
"     15",
"    </a>",
"    ]. However, none of these increases was statistically significant.",
"   </p>",
"   <p>",
"    An increase in the frequency of dysphagia has been noted in all series. This sometimes results from compression of the esophagus by large anterior cervical osteophytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ]. Cervical involvement can also cause hoarseness, stridor, aspiration pneumonia, sleep apnea, atlantoaxial subluxation or pseudoarthrosis, or thoracic outlet syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posterior longitudinal ligament involvement of the cervical spine can result in spinal cord compression and may lead to sensory or motor disturbances due to myelopathy. This can cause devastating neurologic complications, including quadriparesis and quadriplegia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased range of spinal motion, particularly thoracic movement, is the most common finding upon physical examination. Although all spinal motion is diminished in DISH, the loss of thoracic lateral flexion is particularly notable. The likelihood of DISH is increased when diminished thoracic spinal movement occurs in conjunction with tenderness over entheses (eg, sites of attachment of tendons or ligaments to bone). Palpable nodules may also be found at the entheses, with the elbow, knee, and Achilles region being the most common sites.",
"   </p>",
"   <p>",
"    An increased prevalence of Bouchard&rsquo;s and Heberden&rsquo;s nodes in those with DISH compared with age and sex matched controls without DISH was noted in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/34\">",
"     34",
"    </a>",
"    ]; a similar finding relating to Heberden&rsquo;s nodes was noted in a second report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some patients complain of symptoms for years prior to diagnosis, the hallmarks of DISH are radiographic abnormalities. DISH is characterized by the ossification of paravertebral ligaments and peripheral entheses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1,2,6,35-37\">",
"     1,2,6,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Spinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and characteristic radiographic findings involve the thoracic spine, but abnormalities may also be present in the cervical and lumbosacral spine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the thoracic spine, the distinctive finding is flowing linear calcification and ossification along the anterolateral aspects of the vertebral bodies, which continue across the disc space. When present, a lucent area is noted between the anterior longitudinal ligament and the mid-portion of the vertebral body [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/35\">",
"       35",
"      </a>",
"      ]. Thoracic involvement is usually more prominent on the right side of the spine (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68698 \" href=\"mobipreview.htm?9/21/9554\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/2,36\">",
"       2,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the cervical spine (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75500 \" href=\"mobipreview.htm?11/37/11856\">",
"       image 2",
"      </a>",
"      ), hyperostosis occurs initially on the anterior surface of the vertebral body, particularly the inferior lip of the vertebra so that a downward pointing spur arises. Changes are most common in the lower cervical spine.",
"     </li>",
"     <li>",
"      In the lumbar spine, the findings are similar to those of the cervical spine, except that there may be a tendency for the spurs to point upwards. Complete bridging of the lumbar disc space by bone is infrequent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77979 \" href=\"mobipreview.htm?43/48/44802\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The flowing calcification observed in the thoracic region is much less common in the cervical and lumbar locations. A radiograph of the thoracic spine is, therefore, needed for diagnosis. Unlike the thoracic spine in which disc narrowing is mild or nonexistent, disc narrowing can be present in the cervical and lumbar spine. However, marginal sclerosis of the vertebral body, vacuum phenomena, or disc calcification (which are seen in degenerative disc disease) are rare in any spinal region in DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/2,35,36\">",
"     2,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcification or ossification of the posterior longitudinal spinal ligament is a less common finding than is involvement of the anterior counterpart. This arises almost solely in the cervical spine and occurs as a discrete disorder or in association with DISH, ankylosing spondylitis, or spondylosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63686 \" href=\"mobipreview.htm?25/33/26130\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Computed tomography (CT) is more sensitive than plain radiography for detecting posterior longitudinal ligamentous calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/33\">",
"     33",
"    </a>",
"    ]. Neurologic complaints or findings should alert one to the possibility of posterior longitudinal ligament involvement, with associated spinal cord compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extraspinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high frequency of extraspinal involvement has been noted in patients with DISH. Whether DISH occurs in the absence of spinal involvement is uncertain, but it seems possible. Virtually any extraspinal osseous or articular site may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/2,38\">",
"     2,38",
"    </a>",
"    ]. Radiographic changes in the appendicular skeleton are often symmetric.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic and hip involvement includes bony proliferation (also called whiskering), ligament ossification, and periarticular osteophytes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56990 \" href=\"mobipreview.htm?12/28/12751\">",
"       image 5",
"      </a>",
"      ). The whiskering can involve the iliac crest, ischial tuberosity, and trochanter. The iliolumbar and sacrotuberous ligaments can be calcified or ossified, and periarticular osteophytes may be seen at the inferior portion of the sacroiliac joint, the lateral acetabulum, and the superior pubic margins. Heterotopic bone formation may be seen following total hip replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Knees can be involved at the patella, at the insertion of the ligaments, and at the tibial tuberosity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70464 \" href=\"mobipreview.htm?14/25/14751\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ankles and feet can have bony excrescences over the dorsal surface of the talus, the dorsal and medial tarsal navicular, the lateral and plantar aspects of the cuboid, and the base of the fifth metatarsal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54571 graphicRef85821 \" href=\"mobipreview.htm?9/56/10119\">",
"       image 7A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Shoulder involvement includes bony irregularity along the deltoid tuberosity, the inferior glenoid, and the inferior distal clavicle, as well as calcification and ossification of the coracoclavicular ligament.",
"     </li>",
"     <li>",
"      Hand changes include broadening and arrow heading of the phalangeal tufts, enlarged sesamoid bones, thickened cortical width of tubular bones, exostoses, new bone in the joint capsule, and striking proximal phalangeal enthesopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperostosis frontalis interna, a thickening of the inner table of the frontal bones of the skull (usually an incidental radiologic finding of no clinical significance), is increased in DISH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone density is increased in DISH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If DISH coexists with another rheumatic disease, the radiographic appearance of the additional disorder may be unusual. As an example, when patients with rheumatoid arthritis and DISH were assessed radiographically, atypical features included a lack of juxtaarticular osteoporosis, the presence of bone sclerosis and proliferation about erosions, osteophytosis, and bony ankylosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/42\">",
"     42",
"    </a>",
"    ]. Flexion contractures of the elbows, wrists, ankles, or knees were also observed more frequently than expected for patients with rheumatoid arthritis alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no consistent laboratory abnormalities that are associated with DISH. The following are either normal or nondiagnostic: complete blood counts; erythrocyte sedimentation rate; serum levels of calcium, phosphorus, growth hormone, liver enzymes, parathyroid hormone, and fluoride; and the serum protein electrophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1,6,15\">",
"     1,6,15",
"    </a>",
"    ]. The frequency of HLA-B27 is not increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coexistence of DISH with gout, rheumatoid arthritis, Paget disease, and chondrocalcinosis has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/42-45\">",
"     42-45",
"    </a>",
"    ] but has not always been confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/9,15,46\">",
"     9,15,46",
"    </a>",
"    ]. Given the very high prevalence of DISH in older adults, other diseases may coexist independently of any association. As previously mentioned, however, the coexistence of DISH with other diseases, such as rheumatoid arthritis or gout, may alter the radiographic findings of these diseases. In addition, DISH is associated with an increased risk of heterotopic bone formation following total hip replacement in most, but not all, studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1658?source=see_link&amp;anchor=H38#H38\">",
"     \"Complications of total hip arthroplasty\", section on 'Heterotopic ossification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical clues to the presence of DISH include the presence of one or more of the following (",
"    <a class=\"graphic graphic_table graphicRef64311 \" href=\"mobipreview.htm?6/32/6667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized tenderness at peripheral entheses",
"     </li>",
"     <li>",
"      Recurrent Achilles tendinitis",
"     </li>",
"     <li>",
"      Recurrent shoulder &ldquo;bursitis&rdquo;",
"     </li>",
"     <li>",
"      Recurrent lateral or medial epicondylitis",
"     </li>",
"     <li>",
"      Palpable bony spurs (calcaneus, olecranon, patella)",
"     </li>",
"     <li>",
"      Soft tissue mass adherent to quadriceps, patella, or Achilles tendon",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Myelopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic evaluation of the spine, particularly the thoracic spine, should be performed among those suspected of DISH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for the presence of DISH have been proposed by Resnick [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/35\">",
"     35",
"    </a>",
"    ], while Utsinger has recommended different criteria for epidemiologic purposes (",
"    <a class=\"graphic graphic_table graphicRef60298 \" href=\"mobipreview.htm?13/57/14236\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1\">",
"     1",
"    </a>",
"    ]. The Resnick criteria rely solely upon axial radiographic findings and do not include changes present in the peripheral skeleton. The criteria of Utsinger require comparatively less extensive use of radiographs.",
"   </p>",
"   <p>",
"    For screening or epidemiologic studies, a chest radiograph may be used for diagnosis, which will detect at least 75 percent of those with DISH as defined by Resnick&rsquo;s criteria. Patients with less extensive radiographic disease but with skeletal changes consistent with DISH may remain undetected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DISH should be suspected in the patient with characteristic history and physical findings, particularly the presence of restricted motion of the thoracic spine (",
"    <a class=\"graphic graphic_table graphicRef64311 \" href=\"mobipreview.htm?6/32/6667\">",
"     table 1",
"    </a>",
"    ). Appropriate radiographs are subsequently obtained, with results usually diagnostic of DISH.",
"   </p>",
"   <p>",
"    The incidental finding of spinal ligament calcification or ossification may result in a diagnosis of DISH. If the disorder is suspected on the basis of suggestive symptoms or physical findings, as discussed previously (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features'",
"    </a>",
"    above), radiographs of the thoracic spine are suggested as the initial diagnostic test. If previous chest radiographs are available, reviewing them may be sufficient to confirm the diagnosis. Additional radiographic studies may be necessary for those with clinical features suggesting cervical, lumbar, or extraspinal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    A number of conditions may produce spinal bony excrescences similar to those observed with DISH (",
"    <a class=\"graphic graphic_table graphicRef58056 \" href=\"mobipreview.htm?6/56/7051\">",
"     table 3",
"    </a>",
"    ). Of these, the most commonly encountered are spondylosis deformans and ankylosing spondylitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Spondylosis deformans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondylosis deformans is by far the most common of the disorders to be considered in the differential diagnosis of DISH. Although the spurs in the cervical and lumbar spine can resemble those seen in DISH, involvement of the anterior longitudinal ligament in the thoracic spine of DISH is",
"    <strong>",
"     not",
"    </strong>",
"    observed in spondylosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/6,35\">",
"     6,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\", section on 'Cervical spondylosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ankylosing spondylitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis shares some characteristics with DISH, such as a preponderance in males and an association with ligamentous ossification and syndesmophytes. In ankylosing spondylitis, however, the bony bridges are slender, vertical bony bridges that involve the outer margin of the annulus fibrosis and do not involve the anterior longitudinal ligament. In addition, erosions and bony ankylosis of the sacroiliac and apophyseal joints are not seen in DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/6,35\">",
"     6,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74921245\">",
"    <span class=\"h3\">",
"     Ossification of the posterior longitudinal ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ossification of the posterior longitudinal ligament (OPLL) may be seen in up to 50 percent of patients with DISH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/47\">",
"     47",
"    </a>",
"    ] but occurs both independently and in association with other disorders, including ankylosing spondylitis and other spondyloarthropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/48\">",
"     48",
"    </a>",
"    ]. It is more common in east Asian patients but can also be seen in non-Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/33,49\">",
"     33,49",
"    </a>",
"    ]. Unlike DISH, it occurs predominantly in the cervical spine, although thoracic and lumbar OPLL also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/48\">",
"     48",
"    </a>",
"    ]. Most symptomatic patients present with neurologic deficits such as myelopathy or radiculopathy, and surgery is frequently required. Some patients, especially those without myelopathy, do not have progressive disease requiring surgical intervention and may be managed conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of DISH is symptomatic and empiric. There have been no controlled studies examining the effectiveness of any therapy in this disorder. Emphasizing the usually benign nature of DISH may be reassuring to affected patients whose complaints had previously been unexplained.",
"   </p>",
"   <p>",
"    The author&rsquo;s experiences suggest that physical therapy and physical activity are usually beneficial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heat, ultrasound, gentle exercise, and modification of activities of daily living and of recreation can reduce pain.",
"     </li>",
"     <li>",
"      Range of motion exercises and stretching help with stiffness.",
"     </li>",
"     <li>",
"      Range of motion and functional exercise programs to strengthen can increase mobility.",
"     </li>",
"     <li>",
"      Aerobic exercise programs will benefit endurance.",
"     </li>",
"     <li>",
"      Daily swimming is an ideal exercise and can help with weight loss in the obese.",
"     </li>",
"     <li>",
"      Orthotics help with painful heel spurs and assist with ambulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of pain in patients with DISH is similar to that for those with osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild pain frequently responds to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Axial and peripheral joint pain frequently responds to therapy with nonsteroidal antiinflammatory drugs (NSAIDs).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"       Etidronate",
"      </a>",
"      has been suggested as an experimental therapy for DISH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/13,51\">",
"       13,51",
"      </a>",
"      ]. We suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      using etidronate or any other bisphosphonate based upon the limited and preliminary nature of the available data.",
"     </li>",
"     <li>",
"      Local glucocorticoid injections may provide benefit at sites of painful enthesopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=see_link\">",
"       \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"       \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgery is occasionally required to remedy dysphagia caused by large cervical spurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ossification of the posterior longitudinal ligament of the cervical spine can result in progressive myelopathy, which requires surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve root compression and thoracic outlet syndrome may also require surgical intervention; Horner's syndrome, recurrent laryngeal nerve palsy, and vertebral artery insufficiency have also been noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/59/43960/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25490?source=see_link\">",
"       \"Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse idiopathic skeletal hyperostosis (DISH) is a noninflammatory disease, with the principal manifestation being calcification and ossification of spinal ligaments and of peripheral entheses. Radiographic changes characteristic of DISH may occur in the absence of any musculoskeletal symptoms.",
"     </li>",
"     <li>",
"      The etiology and pathogenesis of DISH remain obscure. Possible roles for mechanical factors, dietary components, metabolic disorders, and a genetic predisposition have been suggested. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of DISH varies with the population studied. It is particularly high among the Pima Indians of the United States, is more common in men than women, and is less common in blacks than Caucasians. The prevalence increases with age. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain in the region of the thoracic spine is a common complaint, present in 40 to 80 percent of patients. Morning stiffness, often considered a symptom of inflammatory back pain, may also be present. Dysphagia sometimes results from impingement of cervical osteophytes upon the pharynx. Ossification of the posterior spinal ligament in the cervical spine may cause spinal cord compression. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no diagnostic physical findings, but limited motion of the thoracic spine is the most commonly reported abnormality. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distinctive radiographic finding is flowing linear calcification and ossification along the anterolateral aspects of the vertebral bodies, which continue across the disc space of the thoracic spine. Anatomically, these involve the paravertebral ligaments. Calcification or ossification of the posterior longitudinal ligament arises almost solely in the cervical spine and is better visualized with CT scanning than with plain film radiographs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similar calcification and ossification may be seen at peripheral entheseal sites, including the shoulder, iliac crest, ischial tuberosity, trochanters of the hip, tibial tuberosities, patellae, and bones of the hands",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      feet. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Extraspinal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of DISH is made on the basis of compatible radiographic findings. The differential diagnosis includes spondylosis deformans (cervical or lumbar spondylosis) and ankylosing spondylitis, and these are distinguished by the absence of longitudinal spinal ligamentous calcification in the former and by the presence of slender, nearly vertical syndesmophytes in the latter. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.) We suggest radiographs of the thoracic spine as the initial diagnostic study.",
"     </li>",
"     <li>",
"      Treatment of DISH is symptomatic and empiric. We suggest the use of therapeutic modalities (heat, ultrasound, exercises, and modification of activities of daily living) and orthotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest occasional use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      for mild pain and of NSAIDs for moderate pain and for peripheral joint symptoms of pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stiffness (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Painful enthesopathy that is not adequately controlled by oral agents may respond to local injections of glucocorticoids. Surgery is occasionally required for dysphagia due to cervical spurs, for cervical myelopathy due to ossification of the posterior longitudinal ligament, and for other rare neurologic manifestations. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374832583\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge John M Esdaile, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/1\">",
"      Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/2\">",
"      Resnick D, Shapiro RF, Wiesner KB, et al. Diffuse idiopathic skeletal hyperostosis (DISH) [ankylosing hyperostosis of Forestier and Rotes-Querol]. Semin Arthritis Rheum 1978; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/3\">",
"      Forestier J, Lagier R. Ankylosing hyperostosis of the spine. Clin Orthop Relat Res 1971; 74:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/4\">",
"      Ohishi H, Furukawa K, Iwasaki K, et al. Role of prostaglandin I2 in the gene expression induced by mechanical stress in spinal ligament cells derived from patients with ossification of the posterior longitudinal ligament. J Pharmacol Exp Ther 2003; 305:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/5\">",
"      Schlapbach P, Beyeler C, Gerber NJ, et al. Diffuse idiopathic skeletal hyperostosis (DISH) of the spine: a cause of back pain? A controlled study. Br J Rheumatol 1989; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/6\">",
"      Utsinger PD, Resnick D, Shapiro R. Diffuse skeletal abnormalities in Forestier disease. Arch Intern Med 1976; 136:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/7\">",
"      Abiteboul M, Arlet J, Sarrabay MA, et al. [Metabolism of vitamin A in Forestier-Rot&egrave;s-Qu&eacute;rol hyperostosis]. Rev Rhum Mal Osteoartic 1986; 53:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/8\">",
"      Dougados M, Leporho MA, Esmilaire L, et al. [Plasma levels of vitamins A and E in hyperostosis, ankylosing spondylarthritis and rheumatoid polyarthritis]. Rev Rhum Mal Osteoartic 1988; 55:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/9\">",
"      Troillet N, Gerster JC. [Forestier disease and metabolism disorders. A prospective controlled study of 25 cases]. Rev Rhum Ed Fr 1993; 60:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/10\">",
"      DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986; 315:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/11\">",
"      Moskowitz RW, Boja B, Denko CW. The role of growth factors in degenerative joint disorders. J Rheumatol Suppl 1991; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/12\">",
"      DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/13\">",
"      Sarzi-Puttini P, Atzeni F. New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). Curr Opin Rheumatol 2004; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/14\">",
"      Denko CW, Boja B, Malemud CJ. Intra-erythrocyte deposition of growth hormone in rheumatic diseases. Rheumatol Int 2003; 23:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/15\">",
"      Mata S, Fortin PR, Fitzcharles MA, et al. A controlled study of diffuse idiopathic skeletal hyperostosis. Clinical features and functional status. Medicine (Baltimore) 1997; 76:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/16\">",
"      Sencan D, Elden H, Nacitarhan V, et al. The prevalence of diffuse idiopathic skeletal hyperostosis in patients with diabetes mellitus. Rheumatol Int 2005; 25:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/17\">",
"      Spagnola AM, Bennett PH, Terasaki PI. Vertebral ankylosing hyperostosis (Forestier's disease) and HLA antigens in Pima Indians. Arthritis Rheum 1978; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/18\">",
"      Julkunen H, Heinonen OP, Py&ouml;r&auml;l&auml; K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis 1971; 30:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/19\">",
"      Littlejohn GO, Smythe HA. Marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis. J Rheumatol 1981; 8:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/20\">",
"      Scarpa R, De Brasi D, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab 2004; 89:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/21\">",
"      Denko CW, Malemud CJ. Body mass index and blood glucose: correlations with serum insulin, growth hormone, and insulin-like growth factor-1 levels in patients with diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int 2006; 26:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/22\">",
"      el Miedany YM, Wassif G, el Baddini M. Diffuse idiopathic skeletal hyperostosis (DISH): is it of vascular aetiology? Clin Exp Rheumatol 2000; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/23\">",
"      Kosaka T, Imakiire A, Mizuno F, Yamamoto K. Activation of nuclear factor kappaB at the onset of ossification of the spinal ligaments. J Orthop Sci 2000; 5:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/24\">",
"      Julkunen H, Knekt P, Aromaa A. Spondylosis deformans and diffuse idiopathic skeletal hyperostosis (DISH) in Finland. Scand J Rheumatol 1981; 10:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/25\">",
"      Julkunen H, Heinonen OP, Knekt P, Maatela J. The epidemiology of hyperostosis of the spine together with its symptoms and related mortality in a general population. Scand J Rheumatol 1975; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/26\">",
"      Kiss C, O'Neill TW, Mituszova M, et al. The prevalence of diffuse idiopathic skeletal hyperostosis in a population-based study in Hungary. Scand J Rheumatol 2002; 31:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/27\">",
"      Cassim B, Mody GM, Rubin DL. The prevalence of diffuse idiopathic skeletal hyperostosis in African blacks. Br J Rheumatol 1990; 29:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/28\">",
"      Bloom RA. The prevalence of ankylosing hyperostosis in a Jerusalem population--with description of a method of grading the extent of the disease. Scand J Rheumatol 1984; 13:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/29\">",
"      Castellano DM, Sinacori JT, Karakla DW. Stridor and dysphagia in diffuse idiopathic skeletal hyperostosis (DISH). Laryngoscope 2006; 116:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/30\">",
"      Beyeler C, Schlapbach P, Gerber NJ, et al. Diffuse idiopathic skeletal hyperostosis (DISH) of the shoulder: a cause of shoulder pain? Br J Rheumatol 1990; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/31\">",
"      Beyeler C, Schlapbach P, Gerber NJ, et al. Diffuse idiopathic skeletal hyperostosis (DISH) of the elbow: a cause of elbow pain? A controlled study. Br J Rheumatol 1992; 31:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/32\">",
"      Mader R. Clinical manifestations of diffuse idiopathic skeletal hyperostosis of the cervical spine. Semin Arthritis Rheum 2002; 32:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/33\">",
"      Trojan DA, Pouchot J, Pokrupa R, et al. Diagnosis and treatment of ossification of the posterior longitudinal ligament of the spine: report of eight cases and literature review. Am J Med 1992; 92:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/34\">",
"      Schlapbach P, Beyeler C, Gerber NJ, et al. The prevalence of palpable finger joint nodules in diffuse idiopathic skeletal hyperostosis (DISH). A controlled study. Br J Rheumatol 1992; 31:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/35\">",
"      Resnick D, Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 1976; 119:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/36\">",
"      Harris J, Carter AR, Glick EN, Storey GO. Ankylosing hyperostosis. I. Clinical and radiological features. Ann Rheum Dis 1974; 33:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/37\">",
"      Fornasier VL, Littlejohn G, Urowitz MB, et al. Spinal entheseal new bone formation: the early changes of spinal diffuse idiopathic skeletal hyperostosis. J Rheumatol 1983; 10:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/38\">",
"      Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis (DISH): Forestier's disease with extraspinal manifestations. Radiology 1975; 115:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/39\">",
"      Bundrick TJ, Cook DE, Resnik CS. Heterotopic bone formation in patients with DISH following total hip replacement. Radiology 1985; 155:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/40\">",
"      Littlejohn GO, Urowitz MB, Smythe HA, Keystone EC. Radiographic features of the hand in diffuse idiopathic skeletal hyperostosis (DISH): comparison with normal subjects and acromegalic patients. Radiology 1981; 140:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/41\">",
"      Sahin G, Polat G, Bagis S, et al. Study of axial bone mineral density in postmenopausal women with diffuse idiopathic skeletal hyperostosis related to type 2 diabetes mellitus. J Womens Health (Larchmt) 2002; 11:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/42\">",
"      Resnick D, Curd J, Shapiro RF, Wiesner KB. Radiographic abnormalities of rheumatoid arthritis in patients with diffuse idiopathic skeletal hyperostosis. Arthritis Rheum 1978; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/43\">",
"      Littlejohn GO, Hall S. Diffuse idiopathic skeletal hyperostosis and new bone formation in male gouty subjects. A radiologic study. Rheumatol Int 1982; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/44\">",
"      Mazi&egrave;res B, Jung-Rozenfarb M, Arlet J. [Paget's disease, ankylosing vertebral hyperostosis and hyperostosis frontalis interna]. Sem Hop 1978; 54:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/45\">",
"      Bruges-Armas J, Couto AR, Timms A, et al. Ectopic calcification among families in the Azores: clinical and radiologic manifestations in families with diffuse idiopathic skeletal hyperostosis and chondrocalcinosis. Arthritis Rheum 2006; 54:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/46\">",
"      Mata S, Wolfe F, Joseph L, Esdaile JM. Absence of an association of rheumatoid arthritis and diffuse idiopathic skeletal hyperostosis: a case-control study. J Rheumatol 1995; 22:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/47\">",
"      Resnick D, Guerra J Jr, Robinson CA, Vint VC. Association of diffuse idiopathic skeletal hyperostosis (DISH) and calcification and ossification of the posterior longitudinal ligament. AJR Am J Roentgenol 1978; 131:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/48\">",
"      Saetia K, Cho D, Lee S, et al. Ossification of the posterior longitudinal ligament: a review. Neurosurg Focus 2011; 30:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/49\">",
"      Wang MY, Thambuswamy M. Ossification of the posterior longitudinal ligament in non-Asians: demographic, clinical, and radiographic findings in 43 patients. Neurosurg Focus 2011; 30:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/50\">",
"      Pham MH, Attenello FJ, Lucas J, et al. Conservative management of ossification of the posterior longitudinal ligament. A review. Neurosurg Focus 2011; 30:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/51\">",
"      Fulton JD. Analgesic use of etidronate in Forrestier's disease. Lancet 1992; 340:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43960/abstract/52\">",
"      Jun BY, Yoon KJ, Crockard A. Retro-odontoid pseudotumor in diffuse idiopathic skeletal hyperostosis. Spine (Phila Pa 1976) 2002; 27:E266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5496 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43960=[""].join("\n");
var outline_f42_59_43960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanical factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Environmental factors and diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Spinal involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extraspinal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Spondylosis deformans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ankylosing spondylitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H74921245\">",
"      - Ossification of the posterior longitudinal ligament",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374832583\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5496|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/21/9554\" title=\"diagnostic image 1\">",
"      DISH radiograph thoracic spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/37/11856\" title=\"diagnostic image 2\">",
"      DISH radiographs cervical spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/48/44802\" title=\"diagnostic image 3\">",
"      DISH radiograph lumbar spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/33/26130\" title=\"diagnostic image 4\">",
"      DISH CT cervical spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/28/12751\" title=\"diagnostic image 5\">",
"      DISH radiograph right hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/25/14751\" title=\"diagnostic image 6\">",
"      DISH radiograph knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/38/25199\" title=\"diagnostic image 7A\">",
"      DISH radiograph ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/14/23780\" title=\"diagnostic image 7B\">",
"      X-ray right foot normal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/32/6667\" title=\"table 1\">",
"      Clinical clues DISH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/57/14236\" title=\"table 2\">",
"      Diagnostic criteria for DISH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/56/7051\" title=\"table 3\">",
"      Causes bone excrescences",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25490?source=related_link\">",
"      Patient information: Diffuse idiopathic skeletal hyperostosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43961="Low molecular weight heparin for venous thromboembolic disease";
var content_f42_59_43961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"43\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Low molecular weight heparin for venous thromboembolic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Gary E Raskob, MSc, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/59/43961/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/59/43961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H828165\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is prepared by depolymerization of unfractionated heparin using chemical methods or enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. LMW heparin preparations for clinical use have been produced by several companies (",
"    <a class=\"graphic graphic_table graphicRef78074 \" href=\"mobipreview.htm?25/29/26075\">",
"     table 1",
"    </a>",
"    ). They have an average molecular weight of 4000 to 6500 Daltons; by comparison, commercially available unfractionated heparin has an average molecular weight of 15,000 Daltons. Several LMW heparin preparations have been evaluated by clinical trials. The recommendations contained in this topic review are linked to the strength of the evidence from clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/5\">",
"     5",
"    </a>",
"    ]. A firm recommendation is made only when there is supporting evidence from definitive randomized clinical trials.",
"   </p>",
"   <p>",
"    The current status of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the prevention and treatment of venous thromboembolic disease will be reviewed here. Issues relating to the general prevention of venous thromboembolic disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USAGE GUIDELINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations have different biochemical and pharmacologic properties and are not interchangeable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2,4,6,7\">",
"     2,4,6,7",
"    </a>",
"    ]. Thus, each preparation must be evaluated by clinical trials measuring the outcomes of thromboembolism, bleeding, and mortality. This variability has led to the following communication from the Food and Drug Administration (FDA) in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    \"The FDA is alerting physicians and other health professionals to important considerations in the use of LMW heparins, most particularly to the fact that LMW heparins cannot be used interchangeably, unit for unit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , nor can one individual LMW heparin be used interchangeably with another.\"",
"   </p>",
"   <p>",
"    The decision to use a LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparation for a specific clinical indication should be based upon the available clinical trial data for that particular preparation.",
"   </p>",
"   <p>",
"    Approval for the use of the various LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations in distinct clinical settings differs in Europe, Canada, and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Europe, several LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparations are licensed for the prevention and treatment of venous thromboembolism.",
"     </li>",
"     <li>",
"      In Canada, four preparations are approved by the Health Protection Branch. These are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      . The approved clinical indications differ for the individual LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparations.",
"     </li>",
"     <li>",
"      In the United States, three preparations (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      ) are currently approved by the FDA for different clinical indications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetic properties of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    include a very high bioavailability after subcutaneous injection, a longer half-life than unfractionated heparin, and much less interindividual variation in the anticoagulant response to a given dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2\">",
"     2",
"    </a>",
"    ]. The anticoagulant response (anti-Xa activity) to a fixed dose of LMW heparin is highly correlated with the patient's body weight. These pharmacokinetic properties make it possible to give LMW heparin subcutaneously once or twice daily to patients WITHOUT the need for laboratory monitoring of the anticoagulant response or dose adjustment unless pregnancy, morbid obesity, or renal failure is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/8\">",
"     8",
"    </a>",
"    ]. In the presence of such conditions, anti-Xa level measurement has been recommended for proper dosing.",
"   </p>",
"   <p>",
"    Anti-Xa levels should be measured four hours after subcutaneous injection; the dose of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should be titrated to achieve a level of 0.6 to 1.0 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    if administered twice daily, or 1.0 to 2.0 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    if administered once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/8\">",
"     8",
"    </a>",
"    ]. Some individual LMW heparin preparations have specific dosage recommendations for the very obese and those with marked renal impairment. This subject is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H35#H35\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Special patient groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe Renal Failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the pharmacokinetic response to impaired renal function may differ among LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations, there is no clear recommendation for the dosing of LMW heparins in patients with reduced renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H39#H39\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the United States, in the context of patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    is to be used, a reduced dose of 30 mg should be administered subcutaneously once daily for prophylaxis in medical patients during acute illness, abdominal surgery, or hip or knee replacement surgery. In the treatment of acute deep vein thrombosis in outpatients without pulmonary embolism or inpatients with or without pulmonary embolism a reduced dose of enoxaparin (1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    should be administered subcutaneously once daily along with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For Canada, the clinician is referred to the Compendium of Pharmaceuticals and Specialties for additional guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Obese Patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the United States, using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    for treatment of deep-vein thrombosis, dosage in obese patients should be based on actual body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/9\">",
"     9",
"    </a>",
"    ]. For Canada and the United Kingdom, when using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    for the treatment of acute deep vein thrombosis in obese patients, the single daily dose should not exceed 18,000 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H38#H38\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Obese patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing of LMW heparins in obese patients is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H14#H14\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4029358\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of LMW heparins for the prevention and treatment of venous thromboembolic disease in the pregnant patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link&amp;anchor=H7#H7\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\", section on 'Low molecular weight heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=see_link&amp;anchor=H5#H5\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\", section on 'LMWH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have compared the cost effectiveness of the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    with either unfractionated heparin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for the prevention of venous thrombosis after hip replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, there has been no randomized trial directly comparing enoxaparin with warfarin in patients undergoing knee replacement.",
"   </p>",
"   <p>",
"    The reported cost-effectiveness analyses are based upon comparisons of thrombosis rates across separate trials evaluating prophylaxis with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    . As a result, the differences in thrombosis rates reported based upon comparison across trials may be due to features other than the intervention, such as differences in the patients or center variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16\">",
"     16",
"    </a>",
"    ]. A valid cost-effectiveness comparison of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and warfarin prophylaxis must therefore be based on data from randomized trials directly comparing these alternate approaches.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    sodium and LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/17\">",
"     17",
"    </a>",
"    ] and is based upon a randomized trial of 1436 hip or knee arthroplasty patients which directly compared these treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16\">",
"     16",
"    </a>",
"    ]. The study found that the decision to use LMW heparin or warfarin prophylaxis in patients having major joint replacement surgery is a trade-off based upon finely varying points. LMW heparin was found to be as effective as or even more effective than the more complex prophylaxis with warfarin. This conclusion is sensitive to parameters which may influence the comparative cost-effectiveness, including the cost of the drug, INR monitoring, and the cost associated with major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The analysis also demonstrated that the results are health-care system dependent (Canada versus the United States) since:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In Canada, LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      ) is less costly than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"     </li>",
"     <li>",
"      In the United States, the drug cost for LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      will likely be the principal determinant of relative cost-effectiveness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several economic evaluations compared the cost-effectiveness of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and intravenous unfractionated heparin for the initial treatment of patients with proximal deep vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ]. The results indicate that LMW heparin treatment is at least as effective and safe as well as less costly than intravenous unfractionated heparin treatment. It is important to caution that the findings may not apply to different LMW heparin fractions because these fractions intrinsically differ, and their cost may vary substantially. However, the potential for outpatient therapy in 30 to 40 percent of patients treated with LMW heparin, along with a lower hospital readmission rate for VTE recurrence noted in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/19\">",
"     19",
"    </a>",
"    ], would substantially augment the cost savings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION OF VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been extensively evaluated for the prevention of venous thromboembolism (VTE) by clinical trials performed in Europe and North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2,16,20-26\">",
"     2,16,20-26",
"    </a>",
"    ]. The clinical indications for prophylaxis that have been studied include general abdominothoracic surgery, hip or knee replacement, surgery for fractured hip, stroke, spinal cord injury, lower leg immobilization, and medical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2,20,27,28\">",
"     2,20,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General abdominothoracic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients having general abdominothoracic surgery, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is effective and safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"     20",
"    </a>",
"    ]. The ultimate clinical role of LMW heparin in this context will depend upon its relative cost-effectiveness by comparison to low-dose unfractionated heparin or intermittent pneumatic leg compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hip fracture surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients having surgery for hip fracture, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is effective and safe. The role of LMW heparin in this setting depends upon its relative cost-effectiveness by comparison to other recommended treatments, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , adjusted dose vitamin K antagonists, and low dose unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;One double-blind trial randomly assigned 307 patients undergoing elective neurosurgery to postoperative treatment with compression stockings alone or with 40 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , administered once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients who received enoxaparin had a significantly lower rate of venous thromboembolism (17 versus 32 percent) and an equivalent rate of major hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Major trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    has been shown to be more effective than low-dose unfractionated heparin for preventing venous thromboembolism in patients who have had major trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/30\">",
"     30",
"    </a>",
"    ]. In this randomized trial, LMW heparin was associated with a lower incidence of proximal vein thrombosis confirmed by venography (6 versus 15 percent), a lower incidence of calf-vein thrombosis (31 versus 44 percent), but a higher incidence of major bleeding (2.9 versus 0.6 percent) than was low-dose unfractionated heparin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82993334\">",
"    <span class=\"h2\">",
"     Critically ill patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    was found to be not superior to unfractionated heparin in decreasing the incidence of proximal deep vein thrombosis in critically ill patients. This was shown in a multicenter trial in 3764 intensive care unit patients randomly assigned to treatment with either dalteparin (5000 international units once daily) or unfractionated heparin (5000 international units twice daily) while they were in an intensive care unit. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the rate of proximal deep vein thrombosis, the primary outcome, between those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (5.1 percent) and those receiving unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (5.8 percent; hazard ratio 0.92; 95% CI 0.68-1.23).",
"     </li>",
"     <li>",
"      The proportion of patients with pulmonary embolism was significantly lower with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (1.3 percent) than with unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (2.3 percent; hazard ratio 0.51; 95% CI 0.30-0.88).",
"     </li>",
"     <li>",
"      There was no significant difference in the rates of major bleeding or death between the two study arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Elective hip and knee surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the clinical trials in North America have been performed in patients undergoing either hip or knee replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16,23-26\">",
"     16,23-26",
"    </a>",
"    ]. This section on prevention will therefore emphasize these patient groups. The focus is also on the relative effectiveness and safety of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    sodium, since warfarin has been the most widely used pharmacologic prophylaxis in arthroplasty surgery in North America. By comparison, warfarin is less commonly used in Europe; most European trials in hip replacement have therefore compared LMW heparin with either unfractionated heparin or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2,20,21\">",
"     2,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This review of clinical trials of patients undergoing hip or knee replacement surgery is confined to studies that used routine venography to measure the presence or absence of venous thrombosis, since the noninvasive tests (including B-mode or duplex ultrasound and impedance plethysmography) are insensitive for detecting calf-vein and proximal-vein thrombosis (popliteal, femoral, or iliac vein thrombosis) in the setting of hip or knee replacement. Venography provides a valid measure of the thrombosis rates, and should be bilateral since up to 20 percent of the thrombi are detected only in the",
"    <strong>",
"     nonoperated",
"    </strong>",
"    leg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical trials performed to date include both double-blind and open-label designs. If feasible, a double-blind design is preferable because it provides a more valid assessment of the relative safety of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (eg, bleeding rates) in comparison with other clinical approaches.",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is effective and produces marked risk reductions of 70 to 80 percent in the frequency of thrombosis after hip replacement compared with the use of no prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"     20",
"    </a>",
"    ]. The key issue, however, is the relative efficacy and safety of LMW heparin compared with the prophylactic approaches currently used in clinical practice (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , adjusted dose vitamin K antagonists).",
"   </p>",
"   <p>",
"    In North American, a number of randomized trials have compared the LMW heparins",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in the setting of knee replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16,26,32\">",
"     16,26,32",
"    </a>",
"    ]. In addition, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    in a European trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/22\">",
"     22",
"    </a>",
"    ]. The results of these trials are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef51308 \" href=\"mobipreview.htm?31/37/32348\">",
"     table 2",
"    </a>",
"    ). In each of these studies, LMW heparin was more effective than warfarin; however, the absolute rates of thrombosis remained high. The rates of major bleeding were low for both warfarin and LMW heparin.",
"   </p>",
"   <p>",
"    In the largest trial, the findings of the predefined pooled analysis for hip and knee arthroplasty patients showed that the reduction in the incidence of venous thrombosis with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (31.4 versus 37.4 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) was offset by a small but statistically significant increase (2.8 versus 1.2 percent) in major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16\">",
"     16",
"    </a>",
"    ]. Separate analysis of the 517 patients undergoing knee surgery revealed a statistically significant decrease for all deep vein thrombosis with LMW heparin (45 versus 55 percent with warfarin) and a nonsignificant reduction in proximal deep vein thrombosis (7.8 versus 12.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     LMW heparin versus unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have compared LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with low-dose unfractionated heparin (5000 units subcutaneously every eight hours) in patients undergoing hip replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"     20",
"    </a>",
"    ]. LMW heparin is more effective than and as safe as conventional low-dose unfractionated heparin prophylaxis in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , 30 mg subcutaneously every 12 hours) has also been compared with unfractionated heparin (given as a regimen of 7500 units every 12 hours) in 521 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/25\">",
"     25",
"    </a>",
"    ]. Both regimens were begun 12 to 24 hours postoperatively. The overall deep vein thrombosis rates were similar in the LMW heparin and unfractionated heparin groups (19 versus 23 percent, respectively). A significantly lower frequency of bleeding complications (combined major and minor bleeding) was noted in the patients given LMW heparin (5.1 versus 9.3 percent). It is uncertain, however, whether the lower bleeding rate was due to an intrinsic safety advantage of LMW heparin or to the regimen of unfractionated heparin used, which is not a standard regimen. It is possible that a different unfractionated heparin regimen, such as 6500 units every 12 hours, would have been equally effective but without the increased bleeding observed with the higher dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     LMW heparin versus warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America, there have been a number of randomized trials comparing the LMW heparins",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients having hip replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16,20,24,33,34\">",
"     16,20,24,33,34",
"    </a>",
"    ]. Furthermore, a European trial has also compared the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    with the oral anticoagulant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    in patients undergoing hip replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/22\">",
"     22",
"    </a>",
"    ]. The results of these trials are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71205 \" href=\"mobipreview.htm?40/23/41340\">",
"     table 3",
"    </a>",
"    ). LMW heparin prophylaxis in a high risk dose begun postoperatively is as effective as oral anticoagulants adjusted to maintain the International Normalized Ratio (INR) between 2.0 and 3.0.",
"   </p>",
"   <p>",
"    Major bleeding complications occurred with low frequency in both the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    groups. LMW heparin begun six to eight hours postoperatively using a modified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    regimen was more effective than warfarin (",
"    <a class=\"graphic graphic_table graphicRef71205 \" href=\"mobipreview.htm?40/23/41340\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"     33",
"    </a>",
"    ]. This regimen of LMW heparin administered in close proximity to surgery was also safe, with major bleeding occurring infrequently. The superiority of the close proximity regimen may in the future render the 12 to 24 hour postoperative administration of LMW heparin obsolete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     LMW heparin versus IV dextran",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , 40 mg subcutaneously once daily) has been compared with intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/21\">",
"     21",
"    </a>",
"    ]. Enoxaparin was more effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients having hip replacement surgery, several LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimens have been shown by clinical trials to be effective and associated with a low risk of major bleeding. The specific LMW heparins include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A modified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    regimen administered post-operatively provided superior efficacy versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    without significantly increasing overt bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"     33",
"    </a>",
"    ]. LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is simpler to use because it does not require laboratory monitoring of the anticoagulant effect and dose adjustment.",
"   </p>",
"   <p>",
"    In patients having knee replacement, four LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimens (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    , ardeparin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    ) have been shown to be more effective than oral anticoagulant prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    . However, the absolute thrombosis rates remain high (",
"    <a class=\"graphic graphic_table graphicRef51308 \" href=\"mobipreview.htm?31/37/32348\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TIMING AND DURATION OF PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue is whether prophylaxis should be begun pre- or post-operatively. Many of the European clinical trials have evaluated regimens begun preoperatively, whereas the North American clinical trials have tested prophylaxis begun postoperatively. It is possible that LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    begun preoperatively may be more effective than prophylaxis begun postoperatively, without an increased risk of major bleeding. This issue is now clearer because of a randomized trial published in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20,33,35\">",
"     20,33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal interval for beginning the administration of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for thromboprophylaxis is between two hours preoperatively and six to eight hours postoperatively, with the postoperative regimen appearing to cause slightly less major bleeding. Pre-operative administration of LMW heparin in close proximity to surgery is less desirable due to increased major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"     33",
"    </a>",
"    ]. A modified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    regimen administered post-operatively provided superior efficacy versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    without significantly increased overt bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"     33",
"    </a>",
"    ]. Accordingly, administering the modified LMW heparin regimen post-operatively is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate duration of prophylaxis with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    after hip or knee replacement remains the subject of ongoing research, since the period of risk for the development of deep vein thrombosis may extend beyond the period of some prophylactic treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. One study, for example, demonstrated that in patients undergoing hip replacement, in whom venography is negative at 13 to 15 days postoperatively, there is a significant incidence of deep vein thrombosis developing over the following three to four weeks (19 and 8 percent for calf and proximal deep vein thrombosis, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials demonstrated that continuing prophylaxis for one month, rather than only during the hospitalization phase of 10 to 14 days, results in a reduced incidence of deep vein thrombosis at one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimen evaluated in both studies was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40 mg given once daily). One of these studies, for example, demonstrated that enoxaparin reduced the incidence of proximal vein thrombosis at one month (7 versus 24 percent for placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/40\">",
"     40",
"    </a>",
"    ]. A different North American randomized trial has confirmed the benefit of post-discharge thromboprophylaxis using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    for a total of 35 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional randomized trials of out-of-hospital low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    versus placebo have supported these findings. Indeed, extended LMW heparin prophylaxis showed consistent effectiveness and safety in the trials for venographic deep venous thrombosis and symptomatic venous thromboembolism, regardless of study variations in clinical practice and length of hospital stay. The aggregate findings support the need for extended out-of-hospital prophylaxis in patients undergoing hip arthroplasty surgery (",
"    <a class=\"graphic graphic_table graphicRef74430 \" href=\"mobipreview.htm?11/40/11916\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/42\">",
"     42",
"    </a>",
"    ]. Based upon these data, prophylaxis with LMW heparin should be considered for at least one month following hip replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20,42,43\">",
"     20,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral anticoagulant prophylaxis may be less preferred out-of-hospital. In one study, a significantly higher benefit-risk ratio was observed for patients undergoing elective hip replacement who received extended out-of-hospital prophylaxis with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    versus use of the vitamin K antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    . LMW heparin prophylaxis was at least as effective as oral anticoagulants, but with a marked improvement in safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Extended prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar clinical trials need to be performed in patients undergoing knee replacement in order to determine the optimal duration of thromboprophylaxis in this patient group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Medical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of both short-term and extended duration thromboprophylaxis using LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with acute medical illnesses who may be at risk for venous thromboembolism has been determined in a number of randomized trials and a meta-analysis. This important subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H5137695#H5137695\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H5137702#H5137702\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Extended duration prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have documented the safety and efficacy of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the treatment of established venous thrombosis and thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The clinical trials to date indicate that the simplified therapy provided by LMW heparin may allow patients with uncomplicated proximal vein thrombosis to be treated safely in an outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LMWH has shown similar effectiveness to the usual care vitamin K antagonist treatment for preventing recurrence of venous thromboembolism in a broad-spectrum of patients, enhancing the clinician's therapeutic options for patients with proximal vein thrombosis. Accordingly, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may also be suitable for long-term use in patients with venous thromboembolism who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/51\">",
"     51",
"    </a>",
"    ], and in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been evaluated for the initial treatment of deep venous thrombosis (DVT) by several clinical trials both in Europe and in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/40,47,53-58\">",
"     40,47,53-58",
"    </a>",
"    ]. Two outcome measures have been used to assess the effectiveness of treatment: repeat venography after several days of treatment to assess thrombus size, and clinical outcome on long-term follow-up to determine the incidence of recurrent venous thromboembolism (VTE) documented by objective testing. The latter outcome provides more useful data for the practicing clinician. The results of studies using long-term follow-up to document the clinical outcomes of recurrent VTE and mortality are summarized here. The findings of trials using repeat venography to assess effectiveness have been reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Low molecular weight heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of randomized trials have incorporated long-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/47,48,55-58\">",
"     47,48,55-58",
"    </a>",
"    ]. The LMW heparins evaluated were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    . Three of these trials were performed in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ], two were performed in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/47,56\">",
"     47,56",
"    </a>",
"    ], and one trial was performed in Europe, Australia, and New Zealand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/48\">",
"     48",
"    </a>",
"    ]. A meta-analysis of 11 randomized trials also has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/59\">",
"     59",
"    </a>",
"    ]. With a high degree of consistency, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    given in a fixed dose per kilogram subcutaneously either once or twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/60\">",
"     60",
"    </a>",
"    ] was as effective as continuous intravenous unfractionated heparin for the initial treatment of patients with proximal vein thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82993356\">",
"    <span class=\"h3\">",
"     Outpatient treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of required laboratory monitoring or manipulation of infusion pumps makes the outpatient treatment of DVT with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    feasible; initial trials and a Cochrane review indicate that this approach is safe, effective, associated with a high level of patient satisfaction, and a reduced likelihood to report signs and symptoms of post-thrombotic syndrome and leg ulcers (",
"    <a class=\"graphic graphic_table graphicRef70140 \" href=\"mobipreview.htm?16/35/16955\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Outpatient use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Existing malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cancer and acute VTE, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H18#H18\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Treatment of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have examined the use of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the treatment of pulmonary embolism. One study randomly assigned 1021 patients with symptomatic deep venous thrombosis, pulmonary embolism, or both to treatment with fixed dose, twice daily, subcutaneous reviparin, or adjusted dose, unfractionated, intravenous heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/64\">",
"     64",
"    </a>",
"    ]. Pulmonary embolism was present in approximately one-third of patients, and all patients started therapy with an oral coumarin derivative on the first hospital day. No significant differences in recurrent thromboembolic events, major bleeding, or mortality were found between the two treatment groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of acute pulmonary embolism\", section on 'Anticoagulant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second trial randomly assigned 612 patients with pulmonary embolism not requiring thrombolytic therapy or embolectomy to initial treatment with either once daily, fixed dose, subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    , or adjusted dose, intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/65\">",
"     65",
"    </a>",
"    ]. No significant differences in death, symptomatic recurrent thromboembolism, or major bleeding occurred on days 8 or 90.",
"   </p>",
"   <p>",
"    A third trial randomly assigned 200 patients to receive once daily fixed-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    or dose-adjusted continuous intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/66\">",
"     66",
"    </a>",
"    ]. Significantly fewer patients treated with tinzaparin suffered recurrent thromboembolism (zero versus 7 percent), and rates of bleeding were equivalent among the two treatment groups.",
"   </p>",
"   <p>",
"    The hypothesis has been advanced that LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may in fact be superior to unfractionated heparin. As examples, one subgroup analysis of a randomized trial found a significantly lower rate of recurrent venous thromboembolism among patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    (zero versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/66\">",
"     66",
"    </a>",
"    ], while a meta-analysis suggested a mortality benefit of LMW heparin, although rates of recurrent venous thromboembolism did not differ significantly between LMW and unfractionated heparin groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/59/43961/abstract/46\">",
"     46",
"    </a>",
"    ]. However, no superiority of LMW heparin with regard to mortality or recurrent thromboembolism has yet been demonstrated in prospective randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9926118\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight (LMW) heparins have very high bioavailability after subcutaneous injection, a longer half-life than unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and much less variation in the anticoagulant response to a given dose, which is highly correlated with the patient's body weight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These favorable properties allow LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to be given subcutaneously once or twice daily without laboratory monitoring or dose adjustment in most patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Usage guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the presence of pregnancy, renal failure, or obesity, laboratory monitoring is recommended for proper dosing. Anti-Xa levels should be measured four hours after subcutaneous injection; dosing should be titrated to achieve a level of 0.6 to 1.0 international",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      if administered twice daily, or 1.0 to 2.0 international",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      if administered once daily. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When used in this manner, the LMW heparins can be used on an inpatient as well as outpatient basis for both the prevention and treatment of venous thromboembolism (VTE) in medical and surgical patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention of VTE'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of VTE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/1\">",
"      Salzman EW. Low-molecular-weight heparin: is small beautiful? N Engl J Med 1986; 315:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/2\">",
"      Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994; 46:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/3\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/4\">",
"      White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003; 121:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/5\">",
"      Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102:305S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/6\">",
"      Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/7\">",
"      Nightingale SL. From the Food and Drug Administration. JAMA 1993; 270:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/8\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     AHFS Drug InformationAmerican. Society of Health-System Pharmacists., McEvoy GK (Ed), American Hospital Formulary Service, Bethesda 2005.",
"    </li>",
"    <li>",
"     Murray L. Physicians' Desk Reference. Thompson PDR, Montvale, NJ.",
"    </li>",
"    <li>",
"     Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association, Ottawa, ON, Canada 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/12\">",
"      Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/13\">",
"      O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ 1994; 150:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/14\">",
"      Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/15\">",
"      Rodger M, Bredeson C, Wells PS, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998; 159:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/16\">",
"      Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/17\">",
"      Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/18\">",
"      Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/19\">",
"      Merli G, Ferrufino C, Lin J, et al. Hospital-based costs associated with venous thromboembolism treatment regimens. J Thromb Haemost 2008; 6:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/20\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/21\">",
"      Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. The Danish Enoxaparin Study Group. Arch Intern Med 1991; 151:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/22\">",
"      Hamuly&aacute;k K, Lensing AW, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995; 74:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/23\">",
"      Gent M, Hirsh J, Ginsberg JS, et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996; 93:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/24\">",
"      RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. J Bone Joint Surg Am 1994; 76:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/25\">",
"      Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/26\">",
"      Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/27\">",
"      Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001; 86:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/28\">",
"      Testroote M, Stigter W, de Visser DC, Janzing H. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev 2008; :CD006681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/29\">",
"      Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/30\">",
"      Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/31\">",
"      PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/32\">",
"      Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001; 83-A:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/33\">",
"      Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/34\">",
"      Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997; 79:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/35\">",
"      Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/36\">",
"      Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/37\">",
"      Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/38\">",
"      Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001; 83-A:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/39\">",
"      Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/40\">",
"      Bergqvist D, Benoni G, Bj&ouml;rgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/41\">",
"      Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/42\">",
"      Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/43\">",
"      Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/44\">",
"      Samama CM, Vray M, Barr&eacute; J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/45\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/46\">",
"      Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/47\">",
"      Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/48\">",
"      Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/49\">",
"      Hull R, Pineo G, Brant F. Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal-vein thrombosis. Clin Appl Thromb Hemost 1996; 2(Suppl):S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/50\">",
"      Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/51\">",
"      Veiga F, Escrib&aacute; A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/52\">",
"      Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/53\">",
"      Hull RD, Pineo GF. Low molecular weight heparin treatment of venous thromboembolism. Prog Cardiovasc Dis 1994; 37:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/54\">",
"      Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/55\">",
"      Prandoni P, Lensing AW, B&uuml;ller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/56\">",
"      Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/57\">",
"      Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/58\">",
"      Lindmarker P, Holmstr&ouml;m M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/59\">",
"      Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/60\">",
"      Charbonnier BA, Fiessinger JN, Banga JD, et al. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost 1998; 79:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/61\">",
"      Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/62\">",
"      Schraibman IG, Milne AA, Royle EM. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2001; :CD003076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/63\">",
"      Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/64\">",
"      Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/65\">",
"      Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/59/43961/abstract/66\">",
"      Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160:229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1335 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43961=[""].join("\n");
var outline_f42_59_43961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9926118\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H828165\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USAGE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe Renal Failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Obese Patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4029358\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General abdominothoracic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hip fracture surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Major trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82993334\">",
"      Critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Elective hip and knee surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - LMW heparin versus unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - LMW heparin versus warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - LMW heparin versus IV dextran",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TIMING AND DURATION OF PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82993356\">",
"      - Outpatient treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Existing malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9926118\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1335|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/29/26075\" title=\"table 1\">",
"      Low molecular weight heparins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/37/32348\" title=\"table 2\">",
"      LMWH versus oral anticoagulants knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/23/41340\" title=\"table 3\">",
"      LMWH versus oral anticoagulants hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/40/11916\" title=\"table 4\">",
"      Extended LMW heparin hip repl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/35/16955\" title=\"table 5\">",
"      Outpatient care for VTE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_59_43962="ECG with atrial fibrillation with preexcitation in WPW syndrome";
var content_f42_59_43962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1284px;\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram showing atrial fibrillation with preexcitation in Wolff-Parkinson-White (WPW) syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG in this patient with Wolff-Parkinson-White syndrome shows atrial fibrillation with a rapid ventricular response of over 300 beats per minute and fully aberrant QRS complexes. This results from rapid atrioventricular transmission of impulses via a rapidly conducting accessory pathway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43962=[""].join("\n");
var outline_f42_59_43962=null;
var title_f42_59_43963="RX crypto mening transplant";
var content_f42_59_43963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antifungal treatment recommendations for cryptococcal meningoencephalitis in transplant recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction therapy*",
"       </td>",
"       <td>",
"        Liposomal AmB (3-4 mg/kg per day) OR ABLC (5 mg/kg per day) PLUS flucytosine (100 mg/kg per day)",
"       </td>",
"       <td>",
"        2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Alternatives for induction therapy",
"       </td>",
"       <td>",
"        Liposomal AmB (6 mg/kg per day) OR ABLC (5 mg/kg per day)",
"       </td>",
"       <td>",
"        4-6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AmBd (0.7 mg/kg per day)&bull;",
"       </td>",
"       <td>",
"        4-6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consolidation therapy",
"       </td>",
"       <td>",
"        Fluconazole (400-800 mg per day)",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintenance therapy",
"       </td>",
"       <td>",
"        Fluconazole (200-400 mg per day)",
"       </td>",
"       <td>",
"        6 months to 1 year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ABLC: amphotericin B lipid complex; AmB: amphotericin B; AmBd: amphotericin B deoxycholate.",
"     <br>",
"      * Immunosuppressive management may require sequential or step-wise reductions.",
"      <br>",
"       &bull; Many transplant recipients have been successfully treated with AmBd; however, issues of renal dysfunction with calcineurin inhibitors are important and the effective dose is imprecise.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perfect, JR, Disnukes, WE, Dromer, F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291. Copyright &copy; 2010 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43963=[""].join("\n");
var outline_f42_59_43963=null;
var title_f42_59_43964="Categories of antituberculous drugs";
var content_f42_59_43964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categories of antituberculous drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group one: first-line oral antituberculosis drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        (use all possible drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isoniazid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethambutol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyrazinamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group two: fluoroquinolones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        (use only one, because they share genetic targets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moxifloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gatifloxacin*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group three: injectable antituberculosis drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        (use only one, because they share very similar genetic targets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Capreomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kanamycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amikacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group four: less-effective second-line antituberculosis drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        (use all possible drugs if necessary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethionamide/Prothionamide",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cycloserine/Terizidone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aminosalicylic acid (acid salt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group five: less-effective drugs or drugs on which clinical data are sparse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        (use all necessary drugs if there are less than four from the other groups)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bedaquiline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clofazimine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin with clavulanate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipenem-cilastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clarithromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thioacetazone",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Gatifloxacin has been associated with dysglycemia and is no longer available in the United States.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Prothionamide, terizidone, and thioacetazone are not available in the United States.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Reproduced from: Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43964=[""].join("\n");
var outline_f42_59_43964=null;
var title_f42_59_43965="Androgen range child";
var content_f42_59_43965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical ranges expected for serum androgens and steroid precursors in normal females and premature adrenarche*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       17PREG (ng/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       17PROG (ng/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       11-Deoxy-Cortisol (ng/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cortisol (microgram/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       DHEA-S (microgram/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       DHEA (ng/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Androstenedione (ng/dL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Testosterone (ng/dL)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Baseline (8:00 AM)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children, 1-5 yr old",
"      </td>",
"      <td>",
"       10-105",
"      </td>",
"      <td>",
"       5-115",
"      </td>",
"      <td>",
"       20-160",
"      </td>",
"      <td>",
"       3-20",
"      </td>",
"      <td>",
"       5-35",
"      </td>",
"      <td>",
"       20-130",
"      </td>",
"      <td>",
"       10-50",
"      </td>",
"      <td>",
"       &lt;20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children, 6-10 yr old",
"      </td>",
"      <td>",
"       10-200",
"      </td>",
"      <td>",
"       5-115",
"      </td>",
"      <td>",
"       20-160",
"      </td>",
"      <td>",
"       3-20",
"      </td>",
"      <td>",
"       10-115",
"      </td>",
"      <td>",
"       20-345",
"      </td>",
"      <td>",
"       10-75",
"      </td>",
"      <td>",
"       &lt;20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Premature adrenarche",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        20-350",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        5-115",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        20-160",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        3-20",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        40-130",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        50-600",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        20-75",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        10-35",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Early pubertal girls",
"      </td>",
"      <td>",
"       35-350",
"      </td>",
"      <td>",
"       15-220",
"      </td>",
"      <td>",
"       20-160",
"      </td>",
"      <td>",
"       3-20",
"      </td>",
"      <td>",
"       35-130",
"      </td>",
"      <td>",
"       40-600",
"      </td>",
"      <td>",
"       40-175",
"      </td>",
"      <td>",
"       10-35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adult females, follicular phase&bull;",
"      </td>",
"      <td>",
"       55-360",
"      </td>",
"      <td>",
"       15-150&Delta;",
"      </td>",
"      <td>",
"       20-160",
"      </td>",
"      <td>",
"       3-20",
"      </td>",
"      <td>",
"       75-255",
"      </td>",
"      <td>",
"       100-850",
"      </td>",
"      <td>",
"       60-200",
"      </td>",
"      <td>",
"       20-60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       After ACTH",
"       <sub>",
"        1-24",
"       </sub>",
"       (Cosyntropin). Values are measured 30-60 minutes after &ge;10 microgram/m",
"       <sup>",
"        2",
"       </sup>",
"       IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children, 1-5 yr old",
"      </td>",
"      <td>",
"       45-350",
"      </td>",
"      <td>",
"       50-270",
"      </td>",
"      <td>",
"       95-300",
"      </td>",
"      <td>",
"       17-45",
"      </td>",
"      <td>",
"       5-35",
"      </td>",
"      <td>",
"       25-100",
"      </td>",
"      <td>",
"       15-70",
"      </td>",
"      <td>",
"       &lt;20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children, 6-10 yr old",
"      </td>",
"      <td>",
"       60-650",
"      </td>",
"      <td>",
"       85-300",
"      </td>",
"      <td>",
"       95-300",
"      </td>",
"      <td>",
"       17-45",
"      </td>",
"      <td>",
"       10-115",
"      </td>",
"      <td>",
"       70-320",
"      </td>",
"      <td>",
"       25-100",
"      </td>",
"      <td>",
"       &lt;20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Premature adrenarche",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        80-750",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        85-400",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        95-300",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        17-45",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        40-130",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        80-725",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        25-230",
"       </em>",
"      </td>",
"      <td>",
"       <em>",
"        10-35",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Early pubertal girls",
"      </td>",
"      <td>",
"       150-750",
"      </td>",
"      <td>",
"       90-400",
"      </td>",
"      <td>",
"       95-300",
"      </td>",
"      <td>",
"       17-45",
"      </td>",
"      <td>",
"       35-130",
"      </td>",
"      <td>",
"       70-725",
"      </td>",
"      <td>",
"       55-230",
"      </td>",
"      <td>",
"       10-35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adult females, follicular phase",
"      </td>",
"      <td>",
"       150-1070",
"      </td>",
"      <td>",
"       35-160&Delta;",
"      </td>",
"      <td>",
"       95-300",
"      </td>",
"      <td>",
"       17-45",
"      </td>",
"      <td>",
"       75-255",
"      </td>",
"      <td>",
"       250-1470",
"      </td>",
"      <td>",
"       60-250",
"      </td>",
"      <td>",
"       20-60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist_other\" colspan=\"9\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Conversion multipliers to SI units",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0316 (nmol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0303 (nmol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0289 (nmol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0276 (micromol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0271 (micromol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0347 (nmol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0349 (nmol/L)",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        0.0347 (nmol/L)",
"       </strong>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DHEA: dehydroepiandrosterone; DHEA-S: dehydroepiandrosterone sulfate; 17PREG: 17-hydroxypregnenolone; 17PROG: 17-hydroxyprogesterone.",
"     <br>",
"      * Ranges for radioimmunoassay after preparatory chromatography, except for cortisol and DHEAS. Values differ slightly among laboratories.",
"      <br>",
"       &bull; 17PROG begins rising in the preovulatory phase and peaks as high as 400 ng/dL in the luteal phase of the cycle.",
"       <br>",
"        &Delta; Normal women who are heterozygous for 21-hydroxylase deficiency usually have 17PROG levels &gt;140 ng/dl at baseline, and these women often have responses to ACTH greater than those shown.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rosenfield R. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Endocrinol Metab 2007; 92:787. file://jcem.endojournals.org/. Copyright &copy; 2007 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43965=[""].join("\n");
var outline_f42_59_43965=null;
var title_f42_59_43966="Contents: Adult signs and symptoms";
var content_f42_59_43966=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult signs and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult signs and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute and emergent",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/4/35912\">",
"           Acute urinary retention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/52/9034\">",
"           Approach to the adult patient with syncope in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/27/20920\">",
"           Approach to vaginal bleeding in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/22/25962\">",
"           Assessment and management of the acutely agitated or violent adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/32/34311\">",
"           Evaluation of abnormal behavior in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/39/20090\">",
"           Evaluation of chest pain in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41770\">",
"           Evaluation of the adult with abdominal pain in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/58/27562\">",
"           Evaluation of the adult with acute weakness in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/16/28938\">",
"           Evaluation of the adult with dyspnea in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/49/39704\">",
"           Evaluation of the adult with headache in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/52/40778\">",
"           Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ambulatory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/45/35541\">",
"           Approach to dermatologic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/63/8184\">",
"           Approach to minimal bright red bleeding per rectum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/36/23111\">",
"           Approach to the adult patient with fatigue",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/17/32025\">",
"           Approach to the adult with acute diarrhea in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/11/31927\">",
"           Approach to the adult with fever of unknown origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/47/16120\">",
"           Approach to the adult with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/14/17641\">",
"           Approach to the patient with night sweats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31879\">",
"           Approach to the patient with sensory loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/19/32057\">",
"           Approach to the patient with vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/57/7065\">",
"           Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/36/34375\">",
"           Clinical manifestations and diagnosis of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16312\">",
"           Definition and pathogenesis of chronic pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/30/16874\">",
"           Differential diagnosis of abdominal pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/4/15431\">",
"           Etiologies of fever of unknown origin in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/22/40296\">",
"           Evaluation of chronic pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/17/12569\">",
"           Evaluation of dysphagia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5942\">",
"           Evaluation of nonacute scrotal pathology in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/18/5418\">",
"           Evaluation of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44360\">",
"           Evaluation of the acute scrotum in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/12/17607\">",
"           Evaluation of the red eye",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/36/22087\">",
"           Overview of hiccups",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/11/20665\">",
"           Overview of palpitations in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/60/39879\">",
"           Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/54/10090\">",
"           Pruritus: Etiology and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/58/6058\">",
"           Pruritus: Overview of management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/62/13290\">",
"           Treatment of insomnia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/52/40778\">",
"           Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/36/28233\">",
"           Treatment of primary dysmenorrhea in adult women",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-30BE627D1C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f42_59_43966=[""].join("\n");
var outline_f42_59_43966=null;
var title_f42_59_43967="Effect of dynamic extrathoracic airway obstruction";
var content_f42_59_43967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65386%7EPULM%2F55931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65386%7EPULM%2F55931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of dynamic extrathoracic airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of forced expiration and inspiration in dynamic extrathoracic airway obstruction. Left panel, during forced expiration, intratracheal pressure (P",
"    <sub>",
"     tr",
"    </sub>",
"    ) exceeds the pressure around the airway (P",
"    <sub>",
"     atm",
"    </sub>",
"    ), lessening the obstruction. Right panel, during forced inspiration, when P",
"    <sub>",
"     tr",
"    </sub>",
"    falls below P",
"    <sub>",
"     atm",
"    </sub>",
"    , the obstruction worsens resulting in flow limitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effects of dynamic intrathoracic airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel, during forced expiration, the intrathoracic intratracheal pressure (P",
"    <sub>",
"     tr",
"    </sub>",
"    ) is less than the pleural pressure (P",
"    <sub>",
"     pl",
"    </sub>",
"    ), worsening the obstruction. Right panel, during forced inspiration, P",
"    <sub>",
"     tr",
"    </sub>",
"    exceeds P",
"    <sub>",
"     pl",
"    </sub>",
"    , lessening the degree of obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_59_43967=[""].join("\n");
var outline_f42_59_43967=null;
